Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis

Annals of Internal Medicine

Volumn 163, Issue 1, 2015, Pages 40-51

  Navarese, Eliano Pio ^a   Kołodziejczak, Michalina ^a   Schulze, Volker ^a   Gurbel, Paul A ^b   Tantry, Udaya ^b   Lin, Yingfeng ^a   Brockmeyer, Maximilian ^a   Kandzari, David E ^c   Kubica, Julia M ^d   D'Agostino, Ralph B ^e   Kubica, Jacek ^d   Volpe, Massimo ^f   Agewall, Stefan ^g   Kereiakes, Dean J ^h   Kelm, Malte ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c PIEDMONT HEART INSTITUTE   (United States)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e Boston University   (United States)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONVERTASE SUBTILISIN KEXIN TYPE 9; CONVERTASE SUBTILISIN KEXIN TYPE 9 ANTIBODY; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PLACEBO; SERINE PROTEINASE; UNCLASSIFIED DRUG; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; PCSK9 PROTEIN, HUMAN;

CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INTENTION TO TREAT ANALYSIS; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS; ANGINA, UNSTABLE; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION;

ANGINA, UNSTABLE; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL; CREATINE KINASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84931849550     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-2957     Document Type: Review

References (46)

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889-934. [PMID: 24239923] doi:10.1016/j.jacc.2013.11.002
2. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; European Association for Cardiovascular Prevention & Rehabilitation. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818. [PMID: 21712404] doi:10.1093/eurheartj/ehr158
3. Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, et al. Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am J Cardiol. 2014;114:549-54. [PMID: 24996554] doi:10.1016/j.amjcard.2014.05.035
4. Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther. 2008;6:955-69. [PMID: 18666846] doi:10.1586/14779072.6.7.955
5. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26-35. [PMID: 16490577]
6. Navarese EP, Szczesniak A, Kolodziejczak M, Gorny B, Kubica J, Suryapranata H. Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs. 2014;14:79-87. [PMID: 24174174] doi:10.1007/s40256-013-0053-0
7. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515-24. [PMID: 22811413] doi: 10.1194/jlr.R026658
8. Bays H, Farnier M, Gaudet D, Weiss R, Ruiz JL, Watts GF, et al. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus adding ezetimibe, doubling statin dose or switching statin therapy in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Presented at the American Heart Association Scientific Sessions; Chicago, Illinois; 15-19 November 2014. Accessed at http://my.Americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469655.pdf on 19 November 2014.
9. Ginsberg HN, Rader D, Raal FJ, Guyton J, Lorenzato C, Pordy R, et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Presented at the American Heart Association Scientific Sessions; Chicago, Illinois; 15-19 November 2014. Accessed at http://my.Americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469651.pdf on 19 November 2014.
10. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the PCSK9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015. [Forthcoming]. doi:10.1016/j.ahj.2015.03.004 http://my.Americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_469651.pdf
11. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. March 2011. Accessed at www.cochrane.org/resources/handbook on 1 November 2014.
12. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12. [PMID: 19631508] doi:10.1016/j.jclinepi.2009.06.005
13. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, et al. Friedewald-estimated versus directly measured lowdensity lipoprotein cholesterol and treatment implications. J AmColl Cardiol. 2013;62:732-9. [PMID: 23524048] doi:10.1016/j.jacc.2013.01.079
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
15. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials. 1986;7:267-75. [PMID: 3802849]
16. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351-75. [PMID: 15116347]
17. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-19. [PMID: 24678979] doi:10.1056/NEJMoa1316222
18. Cannon CP, Cariou B, Blom DJ, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study. European Society of Cardiology Congress, Barcelona, Spain, 30 August-3 September 2014. Accessed at http://congress365.escardio.org/Presentation/slides/106389 on 15 April 2015.
19. Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, et al; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebocontrolled, dose-ranging, phase 2 study. Lancet. 2012;380:2007-17. [PMID: 23141813] doi:10.1016/S0140-6736(12)61770-X
20. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study. Circ J. 2014;78:1073-82. [PMID: 24662398]
21. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia (heFH) not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies. European Society of Cardiology Congress, Barcelona, Spain, 30 August-3 September 2014. Accessed at www.escardio.org/about/press/esc-congress-2015/press-conferences/Documents/farnier.pdf on 1 November 2014.
22. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al; MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531-40. [PMID: 24691094] doi:10.1016/j.jacc.2014.03.018
23. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebocontrolled, phase 2 study. Lancet. 2012;380:1995-2006. [PMID: 23141812] doi:10.1016/S0140-6736(12)61771-1
24. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59: 2344-53. [PMID: 22463922] doi:10.1016/j.jacc.2012.03.007
25. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. ODYSSEY ALTERNATIVE: efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance defined by placebo run-in and statin rechallenge arm. Presented at the American Heart Association Scientific Sessions; Chicago, Illinois; 15-19 November 2014. Accessed at http://my.Americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469684.pdf on 19 November 2014.
26. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-17. [PMID: 23129602] doi:10.1161/CIRCULATIONAHA.112.144055
27. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385: 341-50. [PMID: 25282520] doi:10.1016/S0140-6736(14)61374-X
28. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, et al; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331-40. [PMID: 25282519] doi:10.1016/S0140-6736(14)61399-4
29. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870-82. [PMID: 24825642] doi:10.1001/jama.2014.4030
30. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-900. [PMID: 23113833] doi: 10.1056/NEJMoa1201832
31. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176:55-61. [PMID: 25037695] doi:10.1016/j.ijcard.2014.06.049
32. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36. [PMID: 22633824] doi:10.1016/S0140-6736(12)60771-5
33. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541-8. [PMID: 24694531] doi:10.1016/j.jacc.2014.03.019
34. Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497-506. [PMID: 23128163] doi:10.1001/jama.2012.25790
35. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015. [PMID: 25773378]
36. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015. [PMID: 25773607]
37. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90. [PMID: 22607822] doi: 10.1016/S0140-6736(12)60367-5
38. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485-94. [PMID: 25082583] doi:10.1016/j.jacc.2014.02.615
39. Cannon CP. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. American Heart Association Scientific Sessions; Chicago, Illinois; 15-19 November 2014. Accessed at http://my.Americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-469669.pdf on 19 November 2014.
40. Califf RM. Issues facing clinical trials of the future. J Intern Med. 2003;254:426-33. [PMID: 14535963]
41. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30:2705-13. [PMID: 19875386] doi:10.1093/eurheartj/ehp118
42. Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851-60. [PMID: 25169167] doi:10.1016/j.jacc.2014.03.061
43. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). ClinicalTrials.gov: NCT01764633. Accessed at https://clinicaltrials.gov/ct2/show/NCT01764633 on 1 April 2015.
44. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). ClinicalTrials.gov: NCT01663402. Accessed at https://clinicaltrials.gov/ct2/show/NCT01663402 on 1 April 2015.
45. Amgen. PROFICIO: the evolocumab clinical trial program. Backgrounder. 18 March 2014. Accessed at www.multivu.com/assets/7061853/documents/7068153-PROFICIO-Backgrounder-FINAL-3-20-14-original.pdf on 1 April 2015.
46. Sanofi; Regeneron Pharmaceuticals. About the ODYSSEY clinical trial program. 2015. Accessed at www.odysseytrials.com/web/about-odyssey-program on 1 April 2015.